Latest Breaking News On - Christophera viehbacher - Page 8 : vimarsana.com

SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD

FDA Approves Zurzuvae, an Oral Treatment for Postpartum Depression

The FDA has approved Zurzuvae (zuranolone) for the treatment of postpartum depression in adults.

Sage Therapeutics - FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

CAMBRIDGE - Sage Therapeutics, Inc. and Biogen Inc. announced the U.S. Food and Drug Administration approved ZURZUVAETM 50 mg for adults with postpartum depression . ZURZUVAE is the first and...

Biogen Inc.: FDA Approves ZURZUVAE (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

FDA Approves ZURZUVAE™ (zuranolone), the First and Only

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved...

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postp

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45Mental health conditions are the leading cause of maternal mortality1 with PPD among the...

Reata Pharmaceuticals : VOTING AND SUPPORT AGREEMENT

VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 , by and among each stockholder of Reata Pharmaceuticals, Inc., a...

Form DEFA14A BIOGEN INC.